68 related articles for article (PubMed ID: 16103495)
1. Effect of thiazolidinediones on lipid profile.
Madan P
CMAJ; 2005 Aug; 173(4):344; author reply 344-5. PubMed ID: 16103495
[No Abstract] [Full Text] [Related]
2. Thiazolidinediones.
Davidson MB
N Engl J Med; 2005 Jan; 352(2):205-7; author reply 205-7. PubMed ID: 15647589
[No Abstract] [Full Text] [Related]
3. Thiazolidinediones and blood lipids in type 2 diabetes.
van Wijk JP; de Koning EJ; Martens EP; Rabelink TJ
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1744-9. PubMed ID: 12907465
[TBL] [Abstract][Full Text] [Related]
4. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
6. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
7. The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Hanefeld M
Diabetes Obes Metab; 2009 Aug; 11(8):742-56. PubMed ID: 19519869
[TBL] [Abstract][Full Text] [Related]
8. [Pioglitazone].
Aso Y
Nihon Rinsho; 2012 May; 70 Suppl 3():620-6. PubMed ID: 22768588
[No Abstract] [Full Text] [Related]
9. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
Schatz H
Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
[No Abstract] [Full Text] [Related]
10. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
11. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
12. Thiazolidinediones.
Yki-Järvinen H
N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
[No Abstract] [Full Text] [Related]
13. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng CH; Huang TS
Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
[No Abstract] [Full Text] [Related]
16. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.
Parhofer KG; Otto C; Geiss HC; Laubach E; Göke B
Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):49-52. PubMed ID: 15662596
[TBL] [Abstract][Full Text] [Related]
17. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
18. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
[TBL] [Abstract][Full Text] [Related]
19. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice.
Jatwa R; Parmar HS; Panda S; Kar A
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):177-80. PubMed ID: 17697037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
